• 1
    JemalA, MurrayT, WardE, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 10-30.
  • 2
    [no authors listed]. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352: 930-942.
  • 3
    BinesJ, OleskeDM, CobleighMA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718-1729.
  • 4
    BonadonnaG, ValagussaP, MoliterniA, ZambettiM, BrambillaC. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901-906.
  • 5
    GanzPA, GreendaleGA, PetersenL, KahnB, BowerJE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003; 21: 4184-4193.
  • 6
    PartridgeAH, GelberS, PeppercornJ, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22: 4174-4183.
  • 7
    BruningPF, PitMJ, de Jong-BakkerM, van den EndeA, HartA, van EnkA. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990; 61: 308-310.
  • 8
    LoboRA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991; 73: 925-930.
  • 9
    SaartoT, BlomqvistC, ValimakiM, MakelaP, SarnaS, ElomaaI. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997; 15: 1341-1347.
  • 10
    ShapiroCL, HendersonIC. Adjuvant therapy of breast cancer. Hematol Oncol Clin North Am. 1994; 8: 213-231.
  • 11
    WalsheJM, DenduluriN, SwainSM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006; 24: 5769-5779.
  • 12
    CollichioF, PandyaK. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival. Oncology (Williston Park). 1994; 8: 45-52.
  • 13
    PetrekJA, NaughtonMJ, CaseLD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006; 24: 1045-1051.
  • 14
    Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in 1 to 3 axillary lymph nodes. Cancer Res. 1985; 45: 4454-4459.
  • 15
    BiancoAR, Del MastroL, GalloC, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991; 63: 799-803.
  • 16
    FisherB, ShermanB, RocketteH, RedmondC, MargoleseR, FisherER. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer. 1979; 44: 847-857.
  • 17
    GoldhirschA, GelberRD, CastiglioneM. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990; 1: 183-188.
  • 18
    ReynoLM, LevineMN, SkingleyP, ArnoldA, Abu ZahraH. Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. Eur J Cancer. 1992; 29A: 21-23.
  • 19
    FornierMN, ModiS, PanageasKS, NortonL, HudisC. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005; 104: 1575-1579.
  • 20
    ThamYL, SextonK, WeissH, ElledgeR, FriedmanLC, KramerR. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007; 30: 126-132.
  • 21
    FisherB, JeongJH, DignamJ, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001: 62-66.
  • 22
    BaumM, BudzarAU, CuzickJ, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131-2139.
  • 23
    CoombesRC, HallE, GibsonLJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 1081-1092.
  • 24
    DowsettM, RichnerJ. Effects of cytotoxic chemotherapy on ovarian and adrenal steroidogenesis in pre-menopausal breast cancer patients. Oncology. 1991; 48: 215-220.
  • 25
    PoikonenP, SaartoT, ElomaaI, JoensuuH, BlomqvistC. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer. 2000; 36: 43-48.